Disparities in receipt of chemotherapy at the end of life among patients with NSCLC.

Receipt End-of-Life Care
DOI: 10.1200/jco.2025.43.16_suppl.e13746 Publication Date: 2025-05-28T15:41:10Z
ABSTRACT
e13746 Background: Chemotherapy near end-of-life (EOL) may not prolong survival and can cause unnecessary suffering. Little work has explored disparities in futile EOL care receipt among AANHPI subgroups. Using chemotherapy within 30 days of death as a proxy for EOL, we examined treatment disaggregated patients with non-small cell lung cancer (NSCLC). Methods: the National Cancer Database, conducted retrospective analysis adult diagnosed NSCLC (2004-2021) who died diagnosis had known (defined binarily). StataMP 18, calculated adjusted odds ratios 95% confidence intervals across racial/ethnic groups using logistic regression (alpha < 0.05). The included year*race interaction term to examine changes over time by race 0.1). Results: 119,046 individuals 30d diagnosis. Patient demographics were follows: 85.9% White (n = 102,130), 10.81% Black 12,874), 0.52% Southeast Asian 617), 0.72% East 853), 0.15% South 175), 0.29% American Indian/Aleutian/Eskimo 349), 0.13% Pacific Islander 158) 1.59% Other 1,890). was administered 7.1% White, 5.7% Black, 5.8% Asian, 8.1% 9.7% 6.3% Indian/Aleutian/Eskimo, 3.8% Islander, 6.6% patients. 1.42x more likely (P 0.028), 0.77x 0.001), 0.59x 0.037) receive than from 2013-2021 1.95x 0.055) 2013-2021, suggesting significant increase SE patients, that lower rate equitably distributed (SE cohort: 5.4% 2004-2012 cohort; CI: 0.99-3.85, P 0.055, compared decreases reference group). Conclusions: We found increased recent years, trends burdensome this group. should facilitate values-concordant diverse Chemo group & year Racial/Ethnic Group %Patients Receiving Futile (All Years) (2004-2012) (2013-2021) 7.1 8.3 5.5 5.7 6.7 4.6 5.8 5.4 6.3 E 8.1 10.1 S 9.7 12.5 7.4 8.2 4.5 3.8 7.2 1.1 6.6 5.1
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....